Joachim Klement, managing director and research analyst at Panmure Liberum, explains the risks the firm sees on Artificial Intelligence names and discusses the potential for a severe AI-triggered market crash. He speaks on "Bloomberg Open Interest."
SpaceX is acquiring a crucial swath of spectrum from Grain Management. The new spectrum allows SpaceX to beam cell service to devices indoors from its Starlink network of satellites and will be combined with a terrestrial network to connect devices everywhere. Sana Pashankar reports on "Bloomberg Open Interest."
OpenAI is expecting to reach or exceed $70 billion in annualized revenue by the end of the year, driven largely by growth in its enterprise business. Ed Ludlow reports on "Bloomberg Open Interest."
Toro (NASDAQ:TORO) reported second-quarter net income of $0.6 million, down 60.9% from the same period in 2025.
Angelini Industries CEO Sergio Marullo di Condojanni discusses acquisition and growth prospects on "The Pulse with Francine Lacqua" on Oct. 6.
Sheila Kahyaoglu, senior equity research analyst at Jefferies, examines third-quarter results from Delta Air Lines, which cut its full-year earnings outlook on high jet fuel prices. She speaks on "Bloomberg Surveillance."
Gorilla Technology Group (NASDAQ:GRRR) signed a non-binding letter of intent to acquire its first U.S. data center, with completion targeted by the end of November 2026.
Sagimet Biosciences (NASDAQ:SGMT) reported 52-week denifanstat acne results from license partner Ascletis’ Phase 3 extension study, including 57% Investigator’s Global Assessment success.
Profound Medical (NASDAQ:PROF) entered a co-education agreement with Telix Pharmaceuticals to support physician education on imaging-informed prostate care.
Col. Wayne Sanders (Ret.) of Bloomberg Intelligence examines what he calls the "hornet's nest" of increased activity in the Middle East as President Donald Trump said Thursday that the US would not strike Iran before the midterm elections.
Arcutis Biotherapeutics (NASDAQ:ARQT) presented new ZORYVE clinical data in infants with atopic dermatitis and patients with psoriasis at EADV and Fall Clinical.
Teva Pharmaceutical Industries (NYSE:TEVA) received U.S. Food and Drug Administration approval for WELTRUZA, a once-monthly subcutaneous olanzapine injection for adults with schizophrenia.
